Tetragalacturonic acid hydroxymethylester belongs to local hemostatics. It is an antihemorrhagic agent.

Trimethyldiphenylpropylamine (Recipavrin) is a methadon analog with antispasmodic properties. It exerts both musculotropic (antibarium) and anticholinergic action, relieves smooth muscle spasms, e.g. dysmenorrhea and pains associated with gallstones. It was marketed in Sweden in the 1960s as a spasmolytic drug under tradename Recipavrin.

AL3818 (anlotinib) is a receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFR1, VEGFR2/KDR, and VEGFR3), stem cell factor receptor (C-kit), platelet-derived growth factor (PDGFβ), and fibroblast growth factor receptors (FGFR1, FGFR2, and FGFR3). Anlotibib is a kind of innovative medicines approved by State Food and Drug Administration（SFDA:2011L00661) which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. Phase III development is underway for the treatment of thyroid cancer, gastric cancer, leiomyosarcoma; non-small cell lung cancer; synovial sarcoma; thyroid cancer etc.

Thiamine disulfide is a vitamin B1 derivative. It is used as a component of vitamin complexes for the treatment of neurological and other disorders associated with disturbance of metabolic functions influenced by B-complex vitamins, including diabetic polyneuropathy, alcoholic peripheral neuritis and post-influenzal neuropathies, for the treatment of neuritis and neuralgia of the spinal nerves, especially facial paresis, cervical syndrome, low back pain, and ischialgia. It has being shown to be a potent inhibitor of human immunodeficiency virus (type-1) production, suggesting that thiamine disulfide may be important for AIDS chemotherapy.

Sutezolid (PNU-100480, PF-02341272) is an oxazolidinone antibiotic currently in development as a treatment for extensively drug-resistant tuberculosis. It is unaffected by mutations conferring resistance to standard TB drugs

Secalciferol (24,25-DIHYDROXYVITAMIN D 3/24R,25(OH)(2)D(3)) is suggested to be an essential hormone for the process of bone fracture healing, it has a physiological role in human bone and mineral metabolism, leading to an enhancement of osteocalcin synthesis. Secalciferol is possibly to bind a nuclear protein vitamin D receptor (VDR) to the ligand binding domain, which is stereo-specific for Secalciferol. The downstream effect will be triggered after the binding, including the inhibition of calcium channel to regulate the calcium homeostasis, and the following reduction of p53 and Pi-induced cytochrome C translocation

Antimony sodium tartrate (stibophen) is a trivalent antimony compound having the same actions and uses as the potassium tartrate but more water-soluble and less irritant when injected. Antimony sodium tartrate has been used in the treatment of Schistosomiasis since 1918. It is a toxic drug and may cause unpleasant side-effects.This drug is now rarely used in the therapy of leishmaniasis, as drugs which are much better tolerated are available

Trichlorfon (Metrifonate), the organophosphorous cholinesterase inhibitor, O,O-dimethylhydroxy-2,2,2-trichlorethyl-phosphonate, has been used sporadically in the treatment of human schistosomiasis for a decade. It has selective and variable schistosomicidal activity against S. haematobium that results from its partial metabolism to a highly active anti-cholinesterase, dichlorvos. Schistosomal cholinesterase is more susceptible to this metabolite than that of the human host, but transient reductions in both plasma and erythrocyte cholinesterase activity are demonstrable at therapeutic dosage. However, despite early concerns about its potential toxicity, metrifonate is well tolerated and has been used effectively and extensively in large-scale control programmes. Its potential to enhance central nervous system cholinergic neurotransmission led to clinical trials for the treatment of people with Alzheimer's disease (AD).

Clorindione belongs to a class of drugs which are known to be vitamin K antagonists, and is a derivative of phenindione. It has been demonstrated as effective in reducing prothrombin levels in humans and also to reduce serum cholesterol and triglycerides in mice.

Amithiozone, also known as thioacetazone, is an oral antibiotic, which is used in the treatment of tuberculosis. In 1991, the World Health Organization (WHO) recommended replacing thioacetazone with ethambutol in patients with known or suspected HIV infection. Thioacetazone is no longer included in WHO’s recommended first-line treatment for tuberculosis and is now reserved for uncommon situations in which treatment options have been compromised by resistance to other anti-tuberculosis medicines in HIV-negative individuals. Despite the increased recognition of this risk, thioacetazone remained in use mainly in low-income countries because of its low cost. Amithiozone has also been used in trials studying the treatment of Mycobacterium Avium-intracellular Infection. One of the possible mechanism action of the drug is interference with the metabolism of methionine of susceptible tubercle bacilli, which utilize methionine for nucleic acid synthesis.